Talphera - Forum WKN: A3DWPN ISIN: US00444T2096 Kürzel: TLPH Forum: Aktien User: Summer.76

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals up to $116.5 million in potential sales-based milestone payments

👀

AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock https://www.prnewswire.com/news-releases/acelrx-announces-7-5-million-registered-direct-offering-of-common-stock-and-warrants-to-purchase-common-stock-301710152.html

Ist sie vom handel ausgesetzt?

Welches potential steckt hier drin? Das kursziel eines einsamen analysten scheint mir etwas fern ab. Aber gute news sollten bei der aktienzahl schon was auslösen. Was meint ihr?

Was hier los🤣

AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-european-peer-reviewed-publication-supporting-the-benefits-of-sublingual-sufentanil-tablets-for-post-operative-pain-management-in-the-journal-of-clinical-medicine-301698026.html Patients reported lower pain scores, required fewer rescue doses and had a shorter hospital stay than patients receiving continuous femoral nerve block This study of patients following knee replacement surgery adds to a growing database supporting the benefits of using sufentanil sublingual tablets for surgical pain management ...

https://www.marketscreener.com/quote/stock/ACELRX-PHARMACEUTICALS-I-7314079/news/ACELRX-PHARMACEUTICALS-INC-Termination-of-a-Material-Definitive-Agreement-form-8-K-42481562/

Hoffentlich 😁

Klingt vielversprechend, aber auf die Umsetzung wird es ankommen. Die Studie wird hoffentlich ihren Teil dazu beitragen.

Wird aber langsam Zeit

Dies ist eine kleine Stichprobe, aber ziemlich erstaunlich, wie sie eine Gruppe von TKA-Operationspatienten mit ssts und cFNB kontinuierlicher Fentanyl-Nervenblockade verwendeten, und Dsuvia war etwas besser! Wow! Das haut mich um, da ich in Krankenhäusern arbeite und Fentanyl-Nervenblocker verwendet habe. Wie viel Arbeit es für das Personal sein kann, Pumpen einzurichten, häufig zu überwachen und Dsuvia ist nur eine sublinguale Tablette

...zeigte nachbörslich noch Bewegung die Gute... Auf SW wurde eine neue Studie verlinkt: https://stocktwits.com/nazzangr/message/497498117

Volumen darf gerne weiter anziehen 🍀

AcelRx Pharmaceuticals GAAP EPS of -$0.94 beats by $0.26, revenue of $0.51M misses by $0.12M https://seekingalpha.com/news/3907392-acelrx-pharmaceuticals-gaap-eps-of-0_94-beats-0_26-revenue-of-0_51m-misses-0_12m • AcelRx Pharmaceuticals press release (NASDAQ:ACRX): Q3 GAAP EPS of -$0.94 beats by $0.26. • Revenue of $0.51M (-72.6% Y/Y) misses by $0.12M. • Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission • DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year • $20.9 million in cash and short-term investments as of September 30, 2022.

AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corporate-update-301677418.html Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year $20.9 million in cash and short-term investments as of September 30, 2022